INK4a may be a useful surrogate biomarker of cervical neoplasia, Ki-67 and human papillomavirus testing have also been shown to be useful in detecting neoplasia. The screening of women by Pap smear has led to a remarkable decline in the mortality from cervical cancer; however, secondary to subjective criteria, interpretation of Pap smears is subject to marked inter-and intraobserver variability as well as having a relatively low sensitivity for cervical neoplasia on a single sample (as low as 66% sensitivity for biopsy-proven high-grade squamous intraepithelial lesions [HSIL]) (1, 2). Recently, histology, which is thought of as the gold standard for the diagnosis of cervical neoplasia, has also been found to suffer from marked intra-and interobserver variability, and testing for high-risk human papillomavirus (HPV) by Hybrid Capture 2, which has been shown to be very sensitive in the detection of cervical neoplasia and useful in the triaging of ASCUS smears, has a low specificity for cervical neoplasia (1, 3). Thus, new biomarkers that are more sensitive and specific in the detection of cervical neoplasia and more reproducible than cervical cytology are needed. Human papillomaviruses (HPV) are known to be a major causative agent in cervical neoplasia and invasive cervical carcinoma. Many different HPV types associated with cervical neoplasia have been
, biopsy samples (n ‫؍‬ 569: negative, 133; reactive, 75; atypical, 39; low grade, 76; moderate, 80; and severe intraepithelial neoplasia, 113; also, squamous cell carcinoma, 46; adenocarcinoma, 7) were analyzed by immunohistochemistry for expression of p16 INK4a and Ki-67 (n ‫؍‬ 432), as well as by in situ hybridization for human papillomavirus Type 16 (n ‫؍‬ 219). Testing for high-risk human papillomavirus types by polymerase chain reaction and HybridCapture2 was performed on concurrent cervical swab specimens. Recuts of the original blocks were reexamined (n ‫؍‬ 198). Endometrial biopsies (n ‫؍‬ 10) were also analyzed for p16
INK4a expression. Degree of p16 INK4a and Ki-67 expression correlated with degree of cervical neoplasia (P < .001) and with presence of high-risk human papillomavirus types (P < .001). There was no relationship between p16
INK4a overexpression and inflammation or hormonal status. Ki-67 expression correlated with inflammation (P ‫؍‬ 0.003) and was expressed in more reactive and atypical lesions than p16 INK4a (P ‫؍‬ 0.008). Probes for human papillomavirus 16 stained 54% of cervical neoplastic lesions; the degree of staining correlated significantly with degree of neoplasia (P < .001) and p16
INK4a staining (P < .001). Interobserver reproducibility was substantial for p16 INK4a and Ki-67 interpretation (weighted : 0.74 and 0.70, respectively). Expression of p16
INK4a was observed in all endometrial biopsies. Compared with Ki-67 expression and detection of high-risk human papillomavirus, p16
INK4a was less likely to be positive in samples from women with negative, reactive, and atypical biopsies. Although expression of p16 INK4a in endometrial epithelium may be problematic in terms of screening, the potential of p16
INK4a as a screening test warrants investigation.
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The screening of women by Pap smear has led to a remarkable decline in the mortality from cervical cancer; however, secondary to subjective criteria, interpretation of Pap smears is subject to marked inter-and intraobserver variability as well as having a relatively low sensitivity for cervical neoplasia on a single sample (as low as 66% sensitivity for biopsy-proven high-grade squamous intraepithelial lesions [HSIL]) (1, 2) . Recently, histology, which is thought of as the gold standard for the diagnosis of cervical neoplasia, has also been found to suffer from marked intra-and interobserver variability, and testing for high-risk human papillomavirus (HPV) by Hybrid Capture 2, which has been shown to be very sensitive in the detection of cervical neoplasia and useful in the triaging of ASCUS smears, has a low specificity for cervical neoplasia (1, 3) . Thus, new biomarkers that are more sensitive and specific in the detection of cervical neoplasia and more reproducible than cervical cytology are needed. Human papillomaviruses (HPV) are known to be a major causative agent in cervical neoplasia and invasive cervical carcinoma. Many different HPV types associated with cervical neoplasia have been discovered, and they have been subdivided into high-and low-risk categories based on their association with invasive cervical carcinoma (4). This association is based, in part, on the relative affinity that the HPV-type specific oncoproteins E6 and E7 bind to cellular regulatory proteins, specifically, the p53 tumor suppressor protein and the retinoblastoma protein (Rb) (5) . Inactivation of these factors, either by degradation (p53) or functional inactivation (Rb), leads to disruption of the cell cycle and increased proliferation, thought to ultimately give rise to carcinoma. p16 INK4a is a cyclin-dependent kinase inhibitor that regulates the activity of cyclin-dependent kinases 4 and 6 and is often inactivated in many cancers by genetic deletion or hypermethylation (6) . In non-HPV-associated tumors, this inactivation leads to increased cyclin-dependent kinase activity and inactivation of Rb. However, in HPVassociated tumors, inactivation of Rb by E7 leads to markedly increased levels of p16 INK4a . Recent studies have documented overexpression of p16
INK4a not only in cervical intraepithelial neoplasia (CIN) but in cervical cancer as well (6 -10) .
The purpose of this study was to (1) 
MATERIALS AND METHODS
Case Selection
Cervical biopsy/LEEP (loop electrical excision procedure) specimens (n ϭ 597) were obtained from an ongoing study at the University of Washington, the details of which are specified elsewhere (11) . In brief, between December 1997 and October 2000, 4358 women from three Planned Parenthood clinics in Washington state were eligible to participate. Patients enrolled in the study received a gynecological exam, were provided cervical cytology, and were tested for high-risk HPV by Hybrid Capture2 and PCR-based assay. Women with an atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), or Նhigh grade SIL (HSIL) on liquid-based Pap test, or with a positive PCR or Hybrid Capture2 test for high risk HPV types (even with a negative Pap smear), were referred for colposcopy and biopsy. A random sample of women with negative HPV deoxyribonucleic acid (DNA) and cytology results was also referred to colposcopy and biopsy. Repeat HPV testing was performed by both Hybrid Capture2 on Pap test specimens and by PCRbased testing of cervical swab samples that had been placed in standard transport media when taken at the colposcopy visit (11) . The 597 specimens were obtained from 382 different women, of whom 236 contributed only one sample and 146 contributed more than one sample (88 contributed two samples, 47 contributed three samples, and 11 contributed four samples).
Additionally, biopsy samples of invasive cervical carcinoma (n ϭ 48) were obtained from another ongoing study on cervical cancer, this one among African women and conducted in cooperation with the University of Dakar in Senegal. PCR testing for HPV was performed on cervical swab specimens collected in standard transport media at the time of biopsy. The details of the study are specified elsewhere (12) .
The endometrial biopsy samples were randomly selected from the Division of Pathology database at Harborview Medical Center.
All biopsy specimens were fixed with 10% neutral buffered formalin, and sections were processed by conventional methods. Original diagnoses were obtained on the initial H&E slides. In the tables and for analysis, the atypical category encompassed lesions diagnosed as follows: atypical, not otherwise specified (NOS); atypical, favor reactive; and atypical squamous metaplasia. (These are analyzed separately according to the different diagnoses in the Results section.) After additional levels had been obtained for immunohistochemistry, an extra section was cut and stained with H&E ("recut," n ϭ 198) and analyzed by one of the authors (SNA) for the following: (1) the presence of neoplasia, (2) degree of inflammation, (3) the location of the lesion, and (4) the presence of immature squamous metaplasia.
Immunohistochemistry
Immunohistochemistry for p16 INK4a and Ki-67 was performed on 569 and 432 samples, respectively. Four-micrometer sections of formalin fixed paraffin embedded tissue were cut and placed on Superfrost Plus microscope slides. The tissue sections were then deparaffinized and rehydrated through graded alcohols. Endogenous peroxidase activity was blocked by an incubation in 3% H 2 O 2 . Antigen retrieval was carried out with 0.01 M citrate buffer pH 6.0 and microwave heat induction (13) . MTM Laboratories (Heidelberg, Germany) supplied the p16
INK4a antibody. The antibody is directed against the human p16
INK4a tumor suppressor protein. The clone designation is E6H4 and identifies an epitope that is between aa134 -156 of p16
INK4a
. The monoclonal antibody clone MIB-1 from DAKO Corporation (Carpenteria, CA) was used to detect the Ki-67 antigen. The native Ki-67 antigen and the recombinant fragments of the molecule are both detected by this antibody. The dilution of the p16
INK4a and Ki-67 antibodies was 1:800 and 1:50, respectively. Approximately 100 microliters of the primary antibody was applied to each slide. The slides were washed and a biotinylated anti-mouse antibody was applied. After another wash, the avidin-biotin-peroxidase complex was applied. Color development was accomplished by incubation in diaminobenzidine with 3% H 2 O 2 as a substrate. Nickel chloride was used to enhance and modify the color of the diaminobenzidine reaction product. The slides were counterstained in methyl green, dehydrated through graded alcohols, cleared in xylene, and coverslipped with permanent mounting media. Internal or external positive controls (for p16 INK4a , CIN III lesions; for Ki-67, inflammatory cells) and negative controls (substitution of mouse ascites fluid for the primary antibody) were included with every run For p16 INK4a , the results were reported in semiquantitative fashion (negative, or 1ϩ to 3ϩ) based on none, 5-25%, 25-75%, and Ͼ75% of cells immunostained in a lesion. Strong nuclear as well as cytoplasmic staining was considered a positive reaction. Wispy weak cytoplasmic staining present in rare cells (Ͻ5%) was considered Ϯ, and for analysis was grouped into the negative category. For Ki-67, the results were also reported in a semiquantitative fashion as cells in the lower 1/3 of the epithelium staining (i.e., usually basilar cell staining), cells in the middle 1/3-2/3 staining, or cells in the upper 1/3 staining (14). Strong nuclear staining was considered a positive reaction. Stains were analyzed by two authors (SNA and JM) for reproducibility; each was blinded to the other's result.
In Situ Hybridization
Four-micrometer sections were cut and placed onto Probe On Plus slides. The slides were baked at 60°C, then deparaffinized in xylene and rehydrated through a series of graded alcohols. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide. The slides were heated in a microwave oven in 10 mM citrate buffer (15) . Tissue digestion was carried out with pepsin. The slides were postfixed in paraformaldehyde and dehydrated through a series of graded alcohols. A biotinylated HPV 16 DNA probe (DAKO) was used. The HPV 16 probes target regions of the E1, E2, E4, E5, E6, and E7 open reading frames and the upstream regulatory region. The probe was applied to the tissue section, and hybridization was carried out at 37°C overnight. Unbound and mismatched hybrids were removed in a series of stringency washes. Visualization was via horseradish peroxidase (HRP) conjugated streptavidin with tyramide signal amplification, diaminobenzidine (3,3'-diaminobenzidine) as the chromogen, and hydrogen peroxide as the substrate (with nickel chloride enhancement) (16) . The slides were counterstained in methyl green and examined by light microscopy.
HPV in situ hybridization was graded in a semiquantitative fashion (negative or 1ϩ to 3ϩ) based on the percentage of cells staining within a lesion (none, Ͻ25%, 25-75%, or Ͼ75%). Positive controls (known HPV 16 -positive lesions by PCR) and negative controls (hybridization mixture without the labeled probe) were included with each run.
HPV DNA Testing
Before PCR assay, DNA isolation and purification was carried out using the QIAamp DNA Mini Kit (QIAGEN Ltd, Crawley, UK) per the manufacturer's instructions. HPV DNA PCR amplification reactions were then performed using 5' biotinylated MY09, MY11, and HMB01 primers and Amplitaq Gold polymerase. To prevent PCR product carryover, dTTP was replaced by dUTP and Uracil-Nglycosylase (UNG) was added. The human ␤-globin gene was coamplified in the HPV reaction mix using 5' biotinylated primers PC04 and GH20 to monitor specimen adequacy. Two L of each specimen was added to 100 L of reaction mix. PCR amplification was carried out in a Perkin Elmer Thermal Cycler 9600 with the following profile: 95°C for 9 minutes to activate the Amplitaq Gold; 40 cycles of 95°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute each, and a 5-minute terminal extension at 72°C.
HPV DNA typing analysis was performed (according to the manufacturer's specifications) using the reverseline strip test (Roche, Emeryville, CA) to detect high-risk HPV 16 A number of individuals contributed more than one sample to the study analysis, either by providing samples during different visits, or multiple slice/sections of biopsy tissue from the same visit, or both. To account for potential bias caused by women who contributed more than one sample, we performed a regression analysis to adjust for correlated data using Generalized Estimating Equations SAS procedure GENMOD. The adjusted analysis did not differ from the unadjusted analysis, so we present results from the unadjusted analysis.
RESULTS
The degree of p16
INK4a expression correlated well with the degree of cervical neoplasia, and this correlation improved slightly when compared with the recut slide diagnosis (P Ͻ .001; Fig. 1 ; Tables 1 and  2 ). There was very little expression in negative and reactive lesions, with only 11% to 12% showing Ն1ϩ staining (24 of 208 -original diagnosis, 12 of 112 recut diagnosis). 57% of the CIN I cases had Ն1ϩ expression, compared with 75% of CIN II lesions and 91% of CIN III lesions. On the recut diagnosis, 97% of CIN III lesions stained Ն1ϩ. There were 10 (9%) CIN III original diagnosis that did not stain for p16 INK4a , but on review, the majority of these were secondary to the lesion being cut through and not present on the immunohistochemistry (IHC) slide. For the recut diagnosis, there was only 1 (3%) case that did not stain with p16 INK4a , and on review, two of three pathologists agreed that this represented CIN III, whereas the third felt it represented atypical squamous metaplasia. p16
INK4a expression of 1ϩ or greater was present in 89%(47/53) of the invasive carcinomas. Review of negative cases confirmed the carcinoma diagnosis.
Fifty-three of the 571 cases had Ϯ staining (as defined above, wispy faint cytoplasmic staining in rare cells [Ͻ5%] ). This staining did not resemble the true positive staining and on analysis was found to significantly correlate with the presence of inflammation (P ϭ .006). Because Ϯ p16
INK4a staining did not resemble true positive nuclear and cytoplasmic staining, was not associated with the detection of high-risk HPV, and was strongly related to detection of inflammation, it was considered a negative finding for p16
INK4a staining.
Of the atypical lesions (n ϭ 39), 6 (15%) of the original diagnosis showed Ն1ϩ p16
INK4a expression compared with 4 (31%) of the recut diagnosis. Two of these were originally coded as atypical squamous metaplasia (ASM), one atypical favor low-grade dysplasia, one atypical not otherwise specified, and two atypical favor reactive. Of the atypical lesions with p16
INK4a expression, most (4 of 6) had either a history of significant dysplasia, concurrent dysplasia, were high-risk HPV positive, and/or had dysplasia on follow-up. Ki-67 was elevated (intermediate expression) in 2 of 4 of the cases. One case of atypical squamous metaplasia that was p16 INK4a positive had a previous biopsy and Pap that were diagnosed as high-grade dysplasia but only showed atypical squamous metaplasia on the LEEP specimen. The other case of p16
INK4a positive atypical squamous metaplasia lacked high-risk HPV, and the concurrent Pap was negative; unfortunately no follow-up was available for this case.
Ki-67 expression also significantly correlated with the degree of cervical neoplasia (P Ͻ .001; Fig. 1 ; Table 3 ). The expression pattern was similar to that for p16 INK4a in that in CIN I, expression was usually confined to the middle one third of the epithelium, and in CIN III, expression was often present in the upper one third. However, one of the major differences was that Ki-67 expression in the middle one third of the epithelium or higher was present in 29% of both reactive and atypical lesions, whereas only 13% (10/75) of reactive and 15% (6/39) of atypical lesions had Ն1ϩ expression of p16
INK4a
. This difference was statistically significant (P ϭ .008). The intermediate or greater expression of Ki-67 also correlated significantly with inflammation (P ϭ .003), whereas Ն1ϩ expression of p16
INK4a did not correlate with inflammation. The portion of originally diagnosed CIN I lesions expressing Ki-67 above the lower one third of the epithelium was 60%; however, the portion of recut diagnosed CIN I lesions expressing Ki-67 above the lower one third was 83% (10 of 12), implying a significant degree of lesion cut-through in the CIN I lesions. Ki-67 expression was present in 92% (47/51) invasive carcinomas.
HPV 16 in situ hybridization was positive in 54% of the neoplastic lesions overall, and the degree of hybridization also correlated significantly with the degree of neoplasia (P Ͻ .001) and p16
INK4a staining (P Ͻ .001; Table 4 ). Of negative and reactive lesions, 9% and 14%, respectively, were positive for HPV 16 in situ hybridization. The majority of samples (68%) that showed 3ϩ p16
INK4a expression stained positively for HPV 16, and only 12 of 54 (22%) biopsies positive for HPV 16 by in situ hybridization lacked p16
INK4a expression. Only 50% of low-grade lesions (12/24) were positive for HPV 16, as opposed to 64% (32/50) of CIN III lesions. p16 INK4a staining correlated significantly with the presence of high-risk HPV types as measured by INK4a expression based on none to Ͻ5%, 5%-25%, 25%-75%, and Ͼ75% of cells immunostained in a lesion. INK4a expression based on none to Ͻ5%, 5%-25%, 25%-75%, and Ͼ75% of cells immunostained in a lesion. HybridCapture2 or PCR-based testing of cervical swab samples taken concurrently at the biopsy/ colposcopy visit ( Table 5 ). The majority of CIN lesions positive for p16
INK4a were also positive for high-risk HPV by HybridCapture2 (84%); however, HybridCapture2 was positive in 17 (36%) histologically negative cases that were negative with p16 INK4a . PCR results were similar to HybridCapture2 results in that 90% of CIN III cases were positive for both p16
INK4a and high-risk HPV, but PCR was also positive for high-risk HPV in 47% of histologically negative cases.
In the invasive carcinoma samples, p16 INK4a expression was more often detected than high-risk HPV DNA (Table 6 ). p16
INK4a expression was present in 89% of the invasive cervical carcinomas, whereas PCR-based assay only detected HPV DNA in 73% of the cases.
There was no significant difference between p16
INK4a expression in samples positive for HPV 16 versus other high-risk HPV types and no difference in expression in samples positive for one versus multiple high-risk HPV types.
In the endometrial samples, p16
INK4a was strongly expressed in the epithelium of all the samples tested: secretory (4/4), proliferative (3/3), and hyperplastic (1/1) endometrium, as well as endometrial adenocarcinoma (2/2; Fig. 2 ). There was minimal staining of the stromal component. The hormonal status of these patients was not available.
Additional analysis on hormonal status was performed on the patients with cervical neoplasia and revealed that there was no link between p16 
DISCUSSION
Because of the significant inter-and intraobserver variability in interpreting both Pap smears INK4a expression based on none to Ͻ5%, 5%-25%, 25%-75%, and Ͼ75% of cells immunostained in a lesion; grading of HPV 16 in situ hybridization based the percentage of cells staining within a lesion (Ͻ25%, 25%-75%, Ͼ75%). except one. This lesion was not without controversy too, as one of three pathologists categorized it as "atypical squamous metaplasia, cannot rule out high-grade neoplasia."
As far as interobserver reproducibility, our study shows that p16
INK4a immunohistochemistry interpretation is reproducible. The value between a pathologist and a technician in grading the immunohistochemistry ranged from substantial agreement to excellent agreement. This level of agreement is better than that found between pathologists in the ASCUS/Low-grade Triage Study on grading cervical neoplasia on biopsy specimens (1) .
One of the strengths of this study is that it includes a large sample of women with negative, reactive, and atypical biopsies because the criteria for referral to colposcopy included women with negative Pap smears who were HPV DNA positive, in addition to a random sample of women with negative Pap and HPV DNA test results. Thus, our study had a large portion of women with positive HPV results who were negative by cytology and histology. Most studies of biopsy-confirmed cervical dysplasia contain few, if any, HPV positive, histologically and cytologically negative samples for comparison. Such a comparison group is critical for estimating the frequency of detecting specific biomarkers among those who do not have the disease of interest. If the observed frequency is low, it suggests that testing for the particular biomarker will have high specificity (i.e., a low number of falsepositive test results) if used for screening the general population. The design of the study also made it possible to assess multiple biomarkers among a sample of reproductive-aged women from a clinical organization (Planned Parenthood) that provides a high percentage of Pap tests in this country. Women attending such clinics in different parts of the county appear to have similar risk profiles for HPV infection and for abnormal Pap tests, indicating that our results for p16 INK4a and for Ki-67 may be generalizable to reproductive aged women throughout the country (19) .
Some of the limitations of this study are that not all of the tests were performed on all of the specimens. However, consecutive specimens were tested and selection was unbiased as to test results. Furthermore, a better direct comparison of p16 INK4a and Hybrid Capture2 or PCR for high-risk HPV DNA would include ELISA (enzyme-linked immunoassay) testing for p16
INK4a on a cervicovaginal sample, but an ELISA test is not yet available.
